Dr. Sanjay Gupta

And that's a wrap for today's episode.

Thanks again to all of you for sending in your health questions.

Remember, no question is too big, too small, or too embarrassing.

Keep them coming.

We might just answer it on our next show.

Reach out to us, record a voice memo, email it to pagingdrgupta at cnn.com.

That's pagingdrgupta at cnn.com.

Or give us a call 470-396-0832 and leave a message.

Thanks for listening.

Hey there, welcome to Chasing Life.

You know, when Ozempic first hit the market in 2017, it was the start of a revolution.

The medication approved to treat type 2 diabetes was also helping people lose weight.

Sometimes a lot of it.

And that fact did not go unnoticed.

The drug seemed to usher in a paradigm shift in the field of weight management.

Other GLP receptor agonists, as they are called, soon followed.

Magovi, Manjaro, Zepbound.

They helped millions of people do what they had been unable to do before, lose weight, seemingly without effort.

So demand for them surged, no surprise.

And since they're widespread use, so has our understanding of them.